History of comorbidities and survival of ovarian cancer patients, results from the Ovarian Cancer Association Consortium

Albina N.Minlikeeva
Jo L.Freudenheim
Kevin H.Eng
Rikki A.Cannioto
Grace Friel
J.Brian Szender
Brahm Segal
Kunle Odunsi
Paul Mayor
Brenda Diergaarde
Emese Zsiros
Linda Kelemen
Marin Köbel
Helen Steed
Anna de Fazio on behalf of the Australian Ovarian Cancer Study Group
Susan Jordan
Peter A. Fasching
Matthias W. Beckmann
Harvey A.Risch
Mary Anne Rossing
Jennifer A.Doherty
Jenny Chang-Claude
Marc T.Goodman
Thilo Dӧrk
Robert Edwards
Francesmary Modugno
Roberta B.Ness
Keitaro Matsuo
Mika Mizuno
Beth Y.Karlan
Ellen L.Goode
Susanne K. Kjær
Estrid Høgdall
Joellen M.Schildkraut
Kathryn L.Terry
Daniel W. Cramer
Elisa V. Bandera
Lisa Paddock
Lambertus A.Kiemeney
Leon F.Massuger
Rebecca Sutphen
Hoda Anton-Culver
Argyrios Ziegas
Usha Menon
Simon A. Gayther
Susan J. Ramus
Aleksandra Gentry-Maharaj
Celeste Leigh Pearce\textsuperscript{51,52}
Jolanta Kupryjanczyk\textsuperscript{73}
Allan Jensen\textsuperscript{31}
Penelope M Webb\textsuperscript{13}
Kirsten B. Moysich\textsuperscript{1,2,6} on behalf of the Ovarian Cancer Association Consortium

\textsuperscript{1}Department of Cancer Prevention and Control, Roswell Park Cancer Institute, Buffalo, NY, USA
\textsuperscript{2}Department of Epidemiology and Environmental Health, University at Buffalo, Buffalo, NY, USA
\textsuperscript{3}Department of Biostatistics and Bioinformatics, Roswell Park Cancer Institute, Buffalo, NY, USA
\textsuperscript{4}Department of Surgery, Division of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USA
\textsuperscript{5}Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA
\textsuperscript{6}Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA
\textsuperscript{7}Center of Immunotherapy, Roswell Park Cancer Institute, Buffalo, NY, USA
\textsuperscript{8}Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, and University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
\textsuperscript{9}Department of Public Health Sciences, Medical University of South Carolina, Charleston, SC, USA
\textsuperscript{10}Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Alberta, Canada
\textsuperscript{11}Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Royal Alexandra Hospital, Edmonton, Alberta, Canada
\textsuperscript{12}Department of Gynecological Oncology, Westmead Hospital and the Westmead Millenium Institute for Medical Research, The University of Sydney, Sydney, NSW, Australia
\textsuperscript{13}Population Health Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
\textsuperscript{14}University of California at Los Angeles, David Geffen School of Medicine, Department of Medicine, Division of Hematology and Oncology
\textsuperscript{15}University Hospital Erlangen, Department of Gynecology and Obstetrics, Friedrich-Alexander-University Erlangen-Nuremberg, Comprehensive Cancer Center Erlangen Nuremberg, Germany
\textsuperscript{16}Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, CT, USA
\textsuperscript{17}Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
\textsuperscript{18}Department of Epidemiology, The Geisel School of Medicine at Dartmouth Medical, Hanover, NH, USA
\textsuperscript{19}Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany
\textsuperscript{20}University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
\textsuperscript{21}Cancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
\textsuperscript{22}Department of Obstetrics and Gynecology, Hannover Medical School, Hannover, Lower Saxony, Germany
\textsuperscript{23}Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
\textsuperscript{24}Ovarian Cancer Center of Excellence, Womens Cancer Research Program, Magee-Womens Research Institute and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, USA
\textsuperscript{25}Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, USA
\textsuperscript{26}School of Public Health, The University of Texas, Houston, TX, USA
\textsuperscript{27}Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan
\textsuperscript{28}Department of Gynecological Oncology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
Women’s Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA
Department of Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, Minnesota, USA
Department of Virus, Lifestyle and Genes, Danish Cancer Society Research Center, Copenhagen, Denmark
Department of Gynecology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Department of Pathology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
Department of Public Health Sciences, School of Medicine, University of Virginia, Charlottesville, VA, USA
Obstetrics and Gynecology Epidemiology Center, Brigham and Women's Hospital, Boston, MA, USA
Cancer Prevention and Control Program, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA
New Jersey Department of Health and Senior Services, Trenton, NJ, USA
School of Public Health, University of Medicine and Dentistry of New Jersey, Piscataway, NJ, USA
Radboud University Medical Center, Radboud Institute for Health Sciences, Nijmegen, Netherlands
Radboud University Medical Center, Radboud Institute for Molecular Life sciences, Department of Gynaecology, Nijmegen, Netherlands
Epidemiology Center, College of Medicine, University of South Florida, Tampa, Florida, USA
Department of Epidemiology, Center for Cancer Genetics Research & Prevention, School of Medicine, University of California Irvine, Irvine, California, USA
Department of Epidemiology, School of Medicine, University of California Irvine, Irvine, California, USA
Women's Cancer, Institute for Women's Health, University College London, London, United Kingdom
Center for Cancer Prevention and Translational Genomics, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, USA
Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA
School of Women's and Children's Health, University of New South Wales, Sydney, NSW, Australia
The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia
Women's Cancer, Institute for Women's Health, University College London, London, UK
Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, USA
Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA, USA
Department of Pathology and Laboratory Diagnostics, The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland

Running title: comorbidities and ovarian cancer prognosis

Keywords: chronic diseases, comorbidities, ovarian cancer, survival, prognosis

Financial support:
A.N. Minlikeeva was supported by National Cancer Institute (NCI) Interdisciplinary Training Grant in Cancer Epidemiology R25CA113951; J.L. Freudenheim was supported by National Institute of Health (NIH)/NCI (2R25CA113951); G. Friel was supported by NIH/NCI (R01CA095023 and R01CA126841); K.H. Eng was supported by NIH/NLM (K01LM012100) and the Roswell Park Alliance Foundation; J.B. Szender was supported by 5T32CA108456; B.H. Segal was supported by NIH (R01CA188900); K.B. Moysich was supported by NIH/NCI (2R25CA113951, R01CA095023, R01CA126841, P50CA159981) and the Roswell Park Alliance Foundation;
AOV was supported by the Canadian Institutes for Health Research (MOP-86727); AUS was supported by U.S. Army Medical Research and Materiel Command (DAMD17-01-1-0729), National Health & Medical Research Council of Australia (199600 and 400281), Cancer Councils of New South Wales, Victoria, Queensland, South Australia and Tasmania, Cancer Foundation of Western Australia; BAV was supported by ELAN Funds of the University of Erlangen-Nuremberg; CON was supported by NIH (R01-CA074850 and R01-CA080742); DOV was supported by NIH (R01-CA112523 and R01-CA87538); GER was supported by German Federal Ministry of Education and Research, Program of Clinical Biomedical Research (01GB9401) and German Cancer Research Center; HAW was supported by NIH (R01-CA58598, N01-CN-55424 and N01-PC-67001); HJO was supported by Funding:Intramural funding; Rudolf-Bartling Foundation; MAC and MAY were supported by NIH (R01-CA122443, P30-CA15083, P50-CA136393), Mayo Foundation, Minnesota Ovarian Cancer Alliance, and Fred C. and Katherine B; MAL was supported by NIH/NCI (R01-CA61107), Danish Cancer Society (research grant 94 222 52), and the Mermaid I project; NCO was supported by NIH (R01-CA76016) and the DOD (DAMD17-02-1-0666); NEC was supported by NIH (R01-Ca54419 and P50-CA105009) and DOD (W81XWH-10-1-02802); NJO was supported by NIH/NCI (K07 CA095666, K22-CA138563, and P30-CA072720) and the Cancer Institute of New Jersey; NTH was supported by Radboud University Medical Centre; TBO was supported by NIH (R01-CA106414-A2), American Cancer Society (CRTG-00-196-01-CCE), DOD (DAMD17-98-1-8659), and Celma Mastery Ovarian Cancer Foundation; UCI was supported by NIH R01-CA058860, and the Lon V Smith Foundation grant LVS-39420; UKO was funded by The Eve Appeal (The Oak Foundation) and supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre; USC was supported by P01CA17054, P30CA14089, R01CA61132, N01PC67010, R03CA113148, R03CA115195, N01CN025403, and California Cancer Research Program (00-01389V-20170, 2II0200); WOC was supported by Polish Ministry of Science and Higher Education (4 POSC 028 14, 2 PO5A 068 27), The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.

**Corresponding author:** Kirsten B. Moysich, A-316 Carlton House, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263. Phone: 1-716-845-8004; Fax 1-716-845-1126. E-mail: [kirsten.moysich@roswellpark.org](mailto:kirsten.moysich@roswellpark.org)

**Conflict of interest:** No potential conflicts of interest were disclosed.

Word count:…

Total number of tables: 2
Abstract

**Background:** Comorbidities can affect survival of ovarian cancer patients by influencing treatment efficacy. However, little evidence exists on the association between individual concurrent comorbidities and prognosis in ovarian cancer patients.

**Methods:** Among patients diagnosed with invasive ovarian carcinoma who participated in 23 studies included in the Ovarian Cancer Association Consortium, we explored associations between histories of endometriosis, asthma, depression, osteoporosis, and autoimmune, gallbladder, kidney, liver and neurological diseases and overall and progression-free survival. Using Cox proportional hazards regression models adjusted for age at diagnosis, stage of disease, histology, and study site, we estimated pooled hazard ratios and 95% confidence intervals to assess associations between each comorbidity and ovarian cancer outcomes.

**Results:** None of the comorbidities were associated with ovarian cancer outcome in the overall sample nor in strata defined by histological subtype, weight status, age at diagnosis or stage of disease (local/regional vs. advanced).

**Conclusions:** Histories of endometriosis, asthma, depression, osteoporosis, and autoimmune, gallbladder, kidney, liver, or neurologic diseases were not associated with ovarian cancer overall or progression-free survival.

**Impact:** These previously diagnosed chronic diseases do not appear to affect ovarian cancer prognosis.
Introduction

Preexisting chronic diseases among ovarian cancer patients can result in the use of nonstandard treatment regimens (1) or intolerance to the standard treatments (2), therefore, limiting cancer therapy or affecting prognosis in these patients (3). Despite the likely role of comorbidities in ovarian cancer prognosis, detailed evidence regarding associations with particular comorbidities is limited, and results of earlier studies conducted to explore such associations are not consistent (1-6). These studies either did not distinguish among individual comorbidities or had insufficient statistical power to examine associations, particularly for histological subtypes.

Previously we reported on the association between histories of hypertension, heart disease, and diabetes in relation to overall survival (OS) and progression-free survival (PFS) among ovarian cancer patients (7). In this study, using a large multi-national sample of studies participating in the Ovarian Cancer Association Consortium (OCAC), we explore the relationship between other selected common comorbidities and OS and PFS among women diagnosed with ovarian cancer. We hypothesize that these comorbidities are associated with poor ovarian cancer prognosis.

Materials and methods

Our analyses use pooled data from 23 studies. Characteristics of the included studies included are shown in Table 1. Patient-related data were collected by either self- or interviewer-administered questionnaires and/or medical records reviews. These data were obtained from the participating study centers, cleaned, and harmonized. Comorbidities of interest comprise endometriosis, asthma, autoimmune diseases (dermatomyositis, polymyositis, rheumatoid
arthritis, Sjögren’s syndrome, scleroderma, systemic lupus erythematosus, inflammatory bowel disease, Hashimoto’s disease, Grave’s disease, and Type I diabetes), depression/anxiety, osteoporosis, and any kidney, liver, gallbladder, and neurological diseases. For the analyses, the study sample was limited to women with invasive epithelial ovarian cancer and no missing information on vital status, length of follow up at the time of last contact or the comorbidity of interest (varies for each disease).

We used age-, stage-, histology-, and site-adjusted Cox proportional hazards models to explore associations between each comorbidity and ovarian cancer outcomes by calculating pooled hazards ratios (HRs) and their 95% confidence intervals (CIs). We were not able to assess heterogeneity among study-specific HRs due to limited numbers of cases in some studies. No other etiologically or prognostically important available factors appreciably changed observed estimates of age- and stage-adjusted study-specific or overall HRs; therefore, they were not included in any of the models.

In all the models, overall survival (OS) was defined as the time from the date of diagnosis to the date of death or end of follow up, whichever occurred first. Progression-free survival (PFS) was defined as the time from the date of diagnosis to the date when progression status (persistence, recurrence, or death) was determined, or the end of follow-up for cases without identified progression. Cases with no history of the comorbidity of interest were the referent.

We also examined whether or not associations differed according to the main histological subtypes (high-grade serous, low-grade serous, mucinous, endometrioid, and clear cell), overweight status (18.5 kg/m²<body mass index (BMI)<25.0 kg/m² vs. BMI≥25.0 kg/m²), age at diagnosis (<65 vs. ≥65 years), and stage of disease (local/regional vs. advanced). In addition, we examined possible multiplicative interactions by likelihood ratio statistics.
We had 80% power to detect the following risk estimates for OS and PFS respectively: 1.11 and 1.20 for endometriosis, 1.28 and 1.34 for asthma, 1.15 and 1.23 for depression, 1.26 and 1.41 for osteoporosis, 1.22 and 1.27 for autoimmune disease, 1.50 and 1.95 for kidney disease, 1.71 and 1.97 for liver disease, 1.16 and 1.21 for gallbladder disease, and 2.08 and 2.29 for neurological diseases.

**Results**

Results of the analyses are presented in Table 2. No significant associations were observed between histories of endometriosis, asthma, depression, osteoporosis, autoimmune, gallbladder, kidney, liver, and neurological diseases and OS or PFS. Results were also not significant and not different in strata defined by histological subtype, overweight status, age, and stage of disease. No evidence of multiplicative interaction was observed.

**Discussion**

In this large international sample of women diagnosed with invasive ovarian cancer, we did not observe associations between histories of endometriosis, asthma, depression, osteoporosis, and autoimmune, kidney, liver, gallbladder, and neurological diseases and OS and PFS. Results of our study are similar to others reporting no association between presence of comorbidity and survival among ovarian cancer patients (1, 4, 6). Our results are also consistent with those from Hemmkinki et al.(8) that showed no association between autoimmune disease and OS, HR=1.09 (95% CI:0.99-1.20). These results suggest that various comorbidities have little impact on survival for a disease that is already characterized by poor prognosis (4).
Strengths of our study include the large sample of patients with ovarian cancer, allowing for the assessment of associations within histological subtypes as well as potential effect modification. Limitations of this research include the possibility of residual confounding, particularly due to the absence of information on treatment regimen and on comorbidities diagnosed after ovarian cancer diagnosis.

In conclusion, we did not observe evidence of the relationship between selected chronic diseases and OS and PFS among cases diagnosed with invasive epithelial ovarian carcinoma.

Acknowledgements:
The AOV group thanks Jennifer Koziak, Mie Konno, Michelle Darago, Faye Chambers and the Tom Baker Cancer Centre Translational Laboratories. The Australian Ovarian Cancer Study Management Group (D. Bowtell, G. Chenevix-Trench, A. deFazio, D. Gertig, A. Green, P. Webb) and ACS Investigators (A. Green, P. Parsons, N. Hayward, P. Webb, D. Whiteman) thank all the clinical and scientific collaborators (see http://www.aocstudy.org/) and the women for their contribution. The cooperation of the 32 Connecticut hospitals, including Stamford Hospital, in allowing patient access, is gratefully acknowledged (CON). This study was approved by the State of Connecticut Department of Public Health Human Investigation Committee. Certain data used in this study were obtained from the Connecticut Tumor Registry in the Connecticut Department of Public Health. The authors assume full responsibility for analyses and interpretation of these data. The German Ovarian Cancer Study (GER) thanks Ursula Eilber for competent technical assistance. The Hannover-Jena Ovarian Cancer Study (HJO) thanks Rüdiger Klapdor for his help in collecting comorbidity data. UKO study group thanks I. Jacobs, M. Widschwendter, E. Wozniak, A. Ryan, J. Ford and N. Balogun for their contribution to the study.
References

<table>
<thead>
<tr>
<th>Study acronym</th>
<th>Study name</th>
<th>Study location, year of diagnosis</th>
<th>Data collection method</th>
<th>Endometriosis</th>
<th>Asthma</th>
<th>Auto immune</th>
<th>Depression</th>
<th>Osteoporosis</th>
<th>Gallbladder disease</th>
<th>Kidney disease</th>
<th>Liver disease</th>
<th>Neurological disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>AOV</td>
<td>Alberta Ovarian Tumor Types Study</td>
<td>Canada 1978-2010</td>
<td>MRR</td>
<td>MRR: reporting of disease</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>AUS</td>
<td>Australian Ovarian Cancer Study</td>
<td>Australia 2002-2006</td>
<td>Self-completed questionnaire</td>
<td>Q:Ever having disease</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>BAV</td>
<td>Bavarian Ovarian Cancer Studies and Controls</td>
<td>Germany 2002-2006</td>
<td>In-person interview</td>
<td>Q: disease found during surgery</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>CON</td>
<td>Connecticut Ovarian Cancer Study</td>
<td>USA: CT 1998-2003</td>
<td>In-person interview</td>
<td>Q: Disease diagnosed by physician</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>DOV</td>
<td>Disease of the Ovary and their Evaluation Study</td>
<td>USA: WA 2002-2005 (DOV) 2006-2009 (DVE)</td>
<td>In-person interview</td>
<td>Q: Disease diagnosed by physician</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>GER</td>
<td>German Ovarian Cancer Study</td>
<td>Germany 1993-1996</td>
<td>Self-administered questionnaire</td>
<td>Q: Disease diagnosed by physician</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HAW</td>
<td>Hawaii Ovarian Cancer Study</td>
<td>USA: HI 1993-2008</td>
<td>In-person interview</td>
<td>Q: Disease diagnosed by physician</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>HJO</td>
<td>Hannover-Jena Ovarian Cancer Study</td>
<td>Germany 2007-2011</td>
<td>MRR</td>
<td>MRR: reporting of disease</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>LAX</td>
<td>Women's Cancer Program at the Samuel Oschin Comprehensive</td>
<td>USA: CA 1989-present</td>
<td>MRR</td>
<td>MRR: reporting of disease</td>
<td>-</td>
<td>-</td>
<td>MRR: reporting of disease</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Study Code</td>
<td>Study Name</td>
<td>Country/Region</td>
<td>Data Collection Method</td>
<td>Disease Diagnosis</td>
<td>Disease Determination</td>
<td>Disease Reporting</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>---------------------------------------------------------------------------</td>
<td>--------------------------------</td>
<td>------------------------</td>
<td>-------------------</td>
<td>----------------------</td>
<td>-------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAC</td>
<td>Mayo Clinic Case-Only Ovarian Cancer Study</td>
<td>USA: CA, FL, SD, ND, IL, IA, WI</td>
<td>Self-completed questionnaire</td>
<td>Q: Ever diagnosed with disease</td>
<td>Q: Determined based on medication intake</td>
<td>Q: Disease diagnosed by physician</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAL</td>
<td>MALignant OVarian cancer</td>
<td>Denmark</td>
<td>In-person interview</td>
<td>Q: Disease diagnosed by physician</td>
<td>Q: Disease diagnosed by physician</td>
<td>Q: Disease diagnosed by physician</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAY</td>
<td>Mayo Clinic Ovarian Cancer Case-Control Study</td>
<td>USA: MA, SD, ND, IL, IA, WI</td>
<td>In-person interview</td>
<td>Q: Ever diagnosed with disease</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NCO</td>
<td>North Carolina Ovarian Cancer Study</td>
<td>USA: NC</td>
<td>Self-completed questionnaire</td>
<td>Q: Disease diagnosed by physician</td>
<td>Q: Disease diagnosed by physician</td>
<td>Q: Disease diagnosed by physician</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NEC</td>
<td>New England Case-Control Study of Ovarian Cancer</td>
<td>USA: NH and MA</td>
<td>In-person interview</td>
<td>Q: Ever having disease</td>
<td>Q: Ever having disease</td>
<td>Q: Ever having disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NJO</td>
<td>New Jersey Ovarian Cancer Study</td>
<td>USA: NJ</td>
<td>Phone interview</td>
<td>Q: Disease diagnosed by physician</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NTH</td>
<td>Nijmegen Ovarian Cancer Study</td>
<td>Netherlands</td>
<td>Self-completed questionnaires</td>
<td>Q: Disease diagnosed by physician</td>
<td>Q: Disease diagnosed by physician</td>
<td>Q: Disease diagnosed by physician</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TBO</td>
<td>Tampa Bay Ovarian Cancer Study</td>
<td>USA: FL</td>
<td>Self-completed questionnaire</td>
<td>Q: Disease diagnosed by physician</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UCI</td>
<td>University of California, Irvine Ovarian Cancer Study</td>
<td>USA: CA</td>
<td>Self-completed questionnaire</td>
<td>Q: Disease diagnosed by physician</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UKO</td>
<td>United Kingdom Ovarian Cancer Population Study</td>
<td>United Kingdom</td>
<td>Self-completed questionnaire</td>
<td>Q: Disease diagnosed by physician</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>USC</td>
<td>University of Southern California, Study of Lifestyle and Women’s</td>
<td>USA: CA</td>
<td>In-person interview</td>
<td>Q: Diagnosed by physician</td>
<td>-</td>
<td>-</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WOC</td>
<td>Warsaw Ovarian Cancer Study</td>
<td>Poland</td>
<td>Self-administered questionnaire</td>
<td>Ever having disease</td>
<td>Ever having disease</td>
<td>Ever having disease</td>
<td>Ever having disease</td>
<td>Ever having disease</td>
<td>Ever having disease</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----</td>
<td>-----------------------------</td>
<td>--------</td>
<td>---------------------------------</td>
<td>---------------------</td>
<td>---------------------</td>
<td>---------------------</td>
<td>---------------------</td>
<td>---------------------</td>
<td>---------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>


2 Studies that provided information on progression-free survival
Abbreviations used: MRR-medical records review, Q-question.
Table 2. Associations between history of selected comorbidities and overall and progression-free survival: Ovarian Cancer Association Consortium.

<table>
<thead>
<tr>
<th>Comorbidity</th>
<th>Deceased HR(95% CI)(^1)</th>
<th>Progression HR(95% CI)(^2)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>Endometriosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>6356</td>
<td>4824</td>
</tr>
<tr>
<td>Yes</td>
<td>571</td>
<td>853</td>
</tr>
<tr>
<td>Asthma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>2117</td>
<td>1393</td>
</tr>
<tr>
<td>Yes</td>
<td>125</td>
<td>101</td>
</tr>
<tr>
<td>Depression</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>2731</td>
<td>1647</td>
</tr>
<tr>
<td>Yes</td>
<td>439</td>
<td>308</td>
</tr>
<tr>
<td>Osteoporosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>2043</td>
<td>1405</td>
</tr>
<tr>
<td>Yes</td>
<td>170</td>
<td>85</td>
</tr>
<tr>
<td>Autoimmune disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>907</td>
<td>579</td>
</tr>
<tr>
<td>Yes</td>
<td>242</td>
<td>178</td>
</tr>
<tr>
<td>Kidney disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>1739</td>
<td>1317</td>
</tr>
<tr>
<td>Yes</td>
<td>48</td>
<td>37</td>
</tr>
<tr>
<td>Liver disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>2186</td>
<td>1461</td>
</tr>
<tr>
<td>Yes</td>
<td>31</td>
<td>15</td>
</tr>
<tr>
<td>Gallbladder disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>2433</td>
<td>1626</td>
</tr>
<tr>
<td>Yes</td>
<td>438</td>
<td>205</td>
</tr>
<tr>
<td>Neurological disease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>1156</td>
<td>1031</td>
</tr>
<tr>
<td>Yes</td>
<td>17</td>
<td>11</td>
</tr>
</tbody>
</table>

\(^1\) models adjusted for age (continuous), stage (localized, regional, or advanced), histology, and study site

\(^2\) studies included for each comorbidity as presented in Table 1